Lead Clinical Candidate: NOVO-111

 Oncology drugs reach tumors, 

but aren’t retained long enough to drive durable responses.

• PK/BD failures: <0.5% of the ADC accumulates in the tumor
• Rapid washout leads to insufficient exposure duration
• Drives:Significant off-target toxicities
• Incomplete responses
• Resistance
• Narrow therapeutic windows 

Macrocycle Drug Conjugates (MDCs): 

Engineered for selective tumor retention.

• Antigen independent: >10% retention in the tumor
• Selective tumor retention signature 
• Sustained intracellular exposure leads to enhanced durability and efficacy in animal studies